

# Molecular Cancer Therapeutics

*A Journal of the American Association for Cancer Research*

Volume 3, Number 7

July 2004

## Articles

- Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling** ..... 763  
Nathan T. Ihle, Ryan Williams, Sherry Chow, Wade Chew, Margareta I. Berggren, Gillian Paine-Murrieta, Daniel J. Minion, Robert J. Halter, Peter Wipf, Robert Abraham, Lynn Kirkpatrick, and Garth Powis
- Down-regulation of protein kinase C $\eta$  potentiates the cytotoxic effects of exogenous tumor necrosis factor-related apoptosis-inducing ligand in PC-3 prostate cancer cells** ..... 773  
Jürgen Sonnemann, Volker Gekeler, Antje Sagrauske, Cornelia Müller, Hans-Peter Hofmann, and James F. Beck
- Lack of neurotoxicity of the vascular targeting agent ZD6126 following repeated i.v. dosing in the rat** ..... 783  
Steve A. Horner, Sarah Gould, James P. Noakes, Niccola J. Rattray, Sandra L. Allen, Elena Zotova, and Joseph C. Arezzo
- A hybrid fibronectin motif protein as an integrin targeting selective tumor vascular thrombogen** ..... 793  
Cheng Liu, Craig Dickinson, Justin Shobe, Fernando Doñate, Wolfram Ruf, and Thomas Edgington
- Curcumin sensitizes prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L by inhibiting nuclear factor- $\kappa$ B through suppression of I $\kappa$ B $\alpha$  phosphorylation** ..... 803  
Dorrah Deeb, Hao Jiang, Xiaohua Gao, Mikehl S. Hafner, Henry Wong, George Divine, Robert A. Chapman, Scott A. Dulchavsky, and Subhash C. Gautam
- Polyamine catabolism in platinum drug action: Interactions between oxaliplatin and the polyamine analogue  $N^1, N^{11}$ -diethylnorspermine at the level of spermidine/spermine  $N^1$ -acetyltransferase** ..... 813  
Suzanne Hector, Carl W. Porter, Debora L. Kramer, Kimberly Clark, Joshua Prey, Nicholas Kisiel, Paula Diegelman, Ying Chen, and Lakshmi Pendyala
- Role of the transcription factor Ets-1 in cisplatin resistance** ..... 823  
Leigh A. Wilson, Hirotaka Yamamoto, and Gurmit Singh
- Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells** ..... 833  
Zhenfeng Duan, Katherine A. Brakora, and Michael V. Seiden

*contents continued*

Activation of protein kinase C  $\beta$ II/ε-c-Jun NH<sub>2</sub>-terminal kinase pathway and inhibition of mitogen-activated protein/extracellular signal-regulated kinase 1/2 phosphorylation in antitumor invasive activity induced by the polymethoxy flavonoid, nobiletin ..... 839  
Yoshiki Miyata, Takashi Sato, Masamichi Yano, and Akira Ito

*In vitro* evaluation of dimethane sulfonate analogues with potential alkylating activity and selective renal cell carcinoma cytotoxicity ..... 849  
Susan D. Mertins, Timothy G. Myers, Susan L. Holbeck, Wilma Medina-Perez, Elaine Wang, Glenda Kohlhagen, Yves Pommier, and Susan E. Bates

Transcriptional signature of flavopiridol-induced tumor cell death ..... 861  
Xing Lü, William E. Burgan, Michael A. Cerra, Eric Y. Chuang, Mong-Hsun Tsai, Philip J. Tofilon, and Kevin Camphausen

**Commentary** ..... 873  
Gene profiling and the cyclin-dependent kinase inhibitor flavopiridol: What's in a name?  
Steven Grant and Paul Dent


Selenite-induced p53 Ser-15 phosphorylation and caspase-mediated apoptosis in LNCaP human prostate cancer cells ..... 877  
Cheng Jiang, Hongbo Hu, Barbara Malewicz, Zaisen Wang, and Junxuan Lü

**Minireview**

A strategy for cancer prevention: Stimulation of the Nrf2-ARE signaling pathway ..... 885  
Yuesheng Zhang and Gary B. Gordon

Information for Authors ..... i

### On the Cover



Targeting dependent cell surface activation of local thrombosis by a specific tumor vascular thrombogen (STVT). The *top panels* illustrate the ternary complex of the thrombogenic initiation complex TF/FVIIa/FXa (*left*) and STVT/FVIIa/FXa (*right*) on a cell surface. The TF, FVIIa, and FX are *blue, red, and yellow*, respectively. The STVT contains a targeting domain (*blue arrow*) fused with the soluble extracellular domain of TF. The TF domain assembles and provides the required cofactor function for the enzyme FVIIa and for presentation of the substrate FX. Only when properly docked on a supportive anionic plasmalemma microdomain will the construct regain function and initiate the thrombogenic cascade. The *lower panel* is a 3D model of Fn-TF3-218 associated with VIIa docked on a supportive cell surface. The fibronectin domain is *orange*, the TF extracellular domain is *yellow*, and the VIIa is *white*. The cell membrane is *blue* and the catalytic site amino acids of VIIa are highlighted in *red*. For details, see Liu et al. in this issue.